Volunteers enjoying a study

Richmond Pharmacology's new dedicated Japanese recruitment team have successfully delivered 2 Japanese panels for Bridging Studies in November and December this year. We are already ahead of target for our Japanese/Caucasian Bridging Studies requirements in 2005.As a result of the continued growth in the demand for Bridging Studies, Richmond Pharmacology have developed a dedicated in-house approach to the recruitment of Japanese volunteer panels.Wendy Galloway, Head of Volunteer Recruitment, commented: “We recognised the need to introduce a stronger means of recruiting Japanese volunteers. Consequently, in September we recruited 5 bilingual Japanese recruitment managers and have introduced a specialist marketing strategy to support this. I am delighted with the results – in just 2 months since the launch we have successfully delivered 2 Japanese volunteer panels. Our campaigns currently stretch across the UK and Germany and through this approach we are already ahead of target for the New Year's requirements. This means we continue to offer our clients a volunteer recruitment guarantee on every Phase I study.”Richmond Pharmacology is Europe's largest provider of Japanese/Caucasian Bridging Studies and has a dedicated Japanese recruitment brand and department. For more information click here.

Latest news

Richmond Pharmacology Announces Promotion of Dr Priscilla Ochuba to Associate Medical Director

August 1, 2025
Richmond Pharmacology is pleased to announce the promotion of Dr Priscilla Ochuba to Associate Medical Director, effective 1st August 2025.
Read more

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Events

JSCPT 2025

5th –6th December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event